Eptifibatide

Identification

Name
Eptifibatide
Accession Number
DB00063  (BTD00063, BIOD00063)
Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description

Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation.

Protein chemical formula
C35H49N11O9S2
Protein average weight
831.962 Da
Sequences
Not Available
Synonyms
  • Integrelin
  • Intrifiban
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Eptifibatide InjectionSolution0.75 mgIntravenousFresenius KabiNot applicableNot applicableCanada
Eptifibatide InjectionSolution0.75 mgIntravenousTeva2013-04-29Not applicableCanada
Eptifibatide InjectionSolution2 mgIntravenousOmega Laboratories LtdNot applicableNot applicableCanada
Eptifibatide InjectionSolution0.75 mgIntravenousAccord Healthcare LimitedNot applicableNot applicableCanada
Eptifibatide InjectionSolution2 mgIntravenousFresenius KabiNot applicableNot applicableCanada
Eptifibatide InjectionSolution0.75 mgIntravenousMylan PharmaceuticalsNot applicableNot applicableCanada
Eptifibatide InjectionSolution2 mgIntravenousAccord Healthcare LimitedNot applicableNot applicableCanada
Eptifibatide InjectionSolution2 mgIntravenousTeva2013-04-29Not applicableCanada
Eptifibatide InjectionSolution0.75 mgIntravenousOmega Laboratories LtdNot applicableNot applicableCanada
Eptifibatide InjectionSolution2 mgIntravenousMylan PharmaceuticalsNot applicableNot applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EptifibatideInjection75 mg/100mLIntravenousAurobindo Pharma2015-12-08Not applicableUs
EptifibatideInjection20 mg/10mLIntravenousAuro Medics Pharma Llc2015-12-08Not applicableUs
EptifibatideInjection, solution2 mg/mLIntravenousAkorn2017-04-18Not applicableUs
EptifibatideInjection, solution2 mg/mLIntravenousTeva Parenteral Medicines, Inc.2016-07-06Not applicableUs
EptifibatideInjection.75 mg/mLIntravenousAmneal Biosciences2016-12-08Not applicableUs
EptifibatideInjection, solution.75 mg/mLIntravenousAkorn2017-04-18Not applicableUs
EptifibatideInjection20 mg/10mLIntravenousAurobindo Pharma2015-12-08Not applicableUs
EptifibatideInjection200 mg/100mLIntravenousAuro Medics Pharma Llc2015-12-08Not applicableUs
EptifibatideInjection75 mg/100mLIntravenousAuro Medics Pharma Llc2015-12-08Not applicableUs
EptifibatideInjection, solution.75 mg/mLIntravenousTeva Parenteral Medicines, Inc.2015-12-14Not applicableUs
Categories
UNII
NA8320J834
CAS number
188627-80-7

Pharmacology

Indication

For treatment of myocardial infarction and acute coronary syndrome.

Structured Indications
Pharmacodynamics

Eptifibatide is an anti-coagulant that selectively blocks the platelet glycoprotein IIb/IIIa receptor. Eptifibatide is a cyclic heptapeptide derived from a protein found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarus barbouri). It belongs to the class of the so called arginin-glycin-aspartat-mimetics and reversibly binds to platelets.

Mechanism of action

Eptifibatide inhibits platelet aggregation by reversibly binding to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets, thus preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands. Inhibition of platelet aggregation occurs in a dose- and concentration-dependent manner.

TargetActionsOrganism
AIntegrin beta-3Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

Approximately 25%

Metabolism

No major metabolites have been detected in human plasma. Deamidated eptifibatide and other, more polar metabolites have been detected in urine.

Route of elimination
Not Available
Half life

Approximately 2.5 hours

Clearance
  • 55 mL/kg/h [patients with coronary artery disease]
Toxicity

Eptifibatide was not lethal to rats, rabbits, or monkeys when administered by continuous intravenous infusion for 90 minutes at a total dose of 45 mg/kg (about 2 to 5 times the recommended maximum daily human dose on a body surface area basis)

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Eptifibatide Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbciximabEptifibatide may increase the anticoagulant activities of Abciximab.Approved
AcenocoumarolEptifibatide may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Acetylsalicylic acid.Approved, Vet Approved
AloxiprinThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Aloxiprin.Experimental
AlprostadilAlprostadil may increase the anticoagulant activities of Eptifibatide.Approved, Investigational
AlteplaseEptifibatide may increase the anticoagulant activities of Alteplase.Approved
ALX-0081Eptifibatide may increase the anticoagulant activities of ALX-0081.Investigational
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Aminosalicylic Acid.Approved
AnagrelideEptifibatide may increase the anticoagulant activities of Anagrelide.Approved
AncrodEptifibatide may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideAndrographolide may increase the anticoagulant activities of Eptifibatide.Investigational
AnistreplaseEptifibatide may increase the anticoagulant activities of Anistreplase.Approved
Antithrombin III humanEptifibatide may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Apixaban.Approved
AprotininThe therapeutic efficacy of Eptifibatide can be decreased when used in combination with Aprotinin.Approved, Withdrawn
ArdeparinEptifibatide may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanEptifibatide may increase the anticoagulant activities of Argatroban.Approved, Investigational
AstaxanthinEptifibatide may increase the anticoagulant activities of Astaxanthin.Investigational
AzelastineAzelastine may increase the anticoagulant activities of Eptifibatide.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Balsalazide.Approved, Investigational
BatroxobinEptifibatide may increase the anticoagulant activities of Batroxobin.Experimental
BecaplerminEptifibatide may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BemiparinEptifibatide may increase the anticoagulant activities of Bemiparin.Approved, Investigational
BeraprostEptifibatide may increase the anticoagulant activities of Beraprost.Investigational
BivalirudinEptifibatide may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BrinaseEptifibatide may increase the anticoagulant activities of Brinase.Experimental
BuflomedilBuflomedil may increase the anticoagulant activities of Eptifibatide.Experimental
ButylphthalideButylphthalide may increase the anticoagulant activities of Eptifibatide.Investigational
CangrelorEptifibatide may increase the anticoagulant activities of Cangrelor.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Carbaspirin calcium.Experimental, Investigational
CertoparinEptifibatide may increase the anticoagulant activities of Certoparin.Approved, Investigational
CilostazolEptifibatide may increase the anticoagulant activities of Cilostazol.Approved
Citric AcidEptifibatide may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClopidogrelEptifibatide may increase the anticoagulant activities of Clopidogrel.Approved, Nutraceutical
CloricromenEptifibatide may increase the anticoagulant activities of Cloricromen.Experimental
ClorindioneEptifibatide may increase the anticoagulant activities of Clorindione.Experimental
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Collagenase clostridium histolyticum.Approved, Investigational
Dabigatran etexilateEptifibatide may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinEptifibatide may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidEptifibatide may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanEptifibatide may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Eptifibatide.Approved, Investigational
DefibrotideEptifibatide may increase the anticoagulant activities of Defibrotide.Approved, Investigational
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Deoxycholic Acid.Approved
dersalazineThe risk or severity of adverse effects can be increased when Eptifibatide is combined with dersalazine.Investigational
DesirudinEptifibatide may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseEptifibatide may increase the anticoagulant activities of Desmoteplase.Investigational
DextranEptifibatide may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Eptifibatide may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Eptifibatide may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Eptifibatide may increase the anticoagulant activities of Dextran 75.Approved
DicoumarolEptifibatide may increase the anticoagulant activities of Dicoumarol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Diflunisal.Approved
DiphenadioneEptifibatide may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleEptifibatide may increase the anticoagulant activities of Dipyridamole.Approved
DitazoleEptifibatide may increase the anticoagulant activities of Ditazole.Approved, Withdrawn
Drotrecogin alfaEptifibatide may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
Edetic AcidEptifibatide may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanEptifibatide may increase the anticoagulant activities of Edoxaban.Approved
EnoxaparinEptifibatide may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineEpinastine may increase the anticoagulant activities of Eptifibatide.Approved, Investigational
EplivanserinEptifibatide may increase the anticoagulant activities of Eplivanserin.Investigational
eplivanserineEptifibatide may increase the anticoagulant activities of eplivanserine.Investigational
EpoprostenolEpoprostenol may increase the antiplatelet activities of Eptifibatide.Approved
Ethyl biscoumacetateEptifibatide may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ferulic acidEptifibatide may increase the anticoagulant activities of Ferulic acid.Experimental
FibrinolysinEptifibatide may increase the anticoagulant activities of Fibrinolysin.Investigational
FluindioneEptifibatide may increase the anticoagulant activities of Fluindione.Investigational
FondaparinuxEptifibatide may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumEptifibatide may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
GabexateEptifibatide may increase the anticoagulant activities of Gabexate.Investigational
GlucosamineGlucosamine may increase the antiplatelet activities of Eptifibatide.Approved
GuacetisalThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Guacetisal.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Hemoglobin crosfumaril.Experimental
HeparinEptifibatide may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineEptifibatide may increase the anticoagulant activities of Higenamine.Investigational
HydroxytyrosolHydroxytyrosol may increase the anticoagulant activities of Eptifibatide.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Eptifibatide.Approved
IbudilastIbudilast may increase the anticoagulant activities of Eptifibatide.Approved, Investigational
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Eptifibatide.Approved, Nutraceutical
IdraparinuxEptifibatide may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Eptifibatide.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the anticoagulant activities of Eptifibatide.Investigational
IloprostIloprost may increase the antiplatelet activities of Eptifibatide.Approved, Investigational
IndobufenEptifibatide may increase the anticoagulant activities of Indobufen.Investigational
KetanserinKetanserin may increase the anticoagulant activities of Eptifibatide.Investigational
LepirudinEptifibatide may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanEptifibatide may increase the anticoagulant activities of Letaxaban.Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Eptifibatide.Approved, Investigational
LinsidomineLinsidomine may increase the anticoagulant activities of Eptifibatide.Experimental
MelagatranEptifibatide may increase the anticoagulant activities of Melagatran.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Mesalazine.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Methyl salicylate.Approved, Vet Approved
MilrinoneMilrinone may increase the anticoagulant activities of Eptifibatide.Approved
NadroparinEptifibatide may increase the anticoagulant activities of Nadroparin.Approved
NafamostatEptifibatide may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftopidilNaftopidil may increase the anticoagulant activities of Eptifibatide.Investigational
NimesulideNimesulide may increase the anticoagulant activities of Eptifibatide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Nitroaspirin.Investigational
ObinutuzumabThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Obinutuzumab.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Olsalazine.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Eptifibatide.Approved, Nutraceutical
OtamixabanEptifibatide may increase the anticoagulant activities of Otamixaban.Investigational
OzagrelEptifibatide may increase the anticoagulant activities of Ozagrel.Investigational
ParnaparinEptifibatide may increase the anticoagulant activities of Parnaparin.Approved, Investigational
Pentaerythritol TetranitrateEptifibatide may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Eptifibatide.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Eptifibatide.Approved, Investigational
PhenindioneEptifibatide may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonEptifibatide may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PicotamideEptifibatide may increase the anticoagulant activities of Picotamide.Experimental
PrasugrelEptifibatide may increase the anticoagulant activities of Prasugrel.Approved
Protein CEptifibatide may increase the anticoagulant activities of Protein C.Approved
Protein S humanEptifibatide may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeEptifibatide may increase the anticoagulant activities of Protocatechualdehyde.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Eptifibatide.Investigational
ResveratrolResveratrol may increase the anticoagulant activities of Eptifibatide.Approved, Experimental, Investigational
ReteplaseEptifibatide may increase the anticoagulant activities of Reteplase.Approved
ReviparinEptifibatide may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelRidogrel may increase the anticoagulant activities of Eptifibatide.Approved
RivaroxabanEptifibatide may increase the anticoagulant activities of Rivaroxaban.Approved
RosiglitazoneEptifibatide may increase the anticoagulant activities of Rosiglitazone.Approved, Investigational
Salicylic acidThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Salicylic acid.Approved, Vet Approved
SarpogrelateEptifibatide may increase the anticoagulant activities of Sarpogrelate.Investigational
SaruplaseEptifibatide may increase the anticoagulant activities of Saruplase.Experimental
SelexipagEptifibatide may increase the anticoagulant activities of Selexipag.Approved
SevofluraneSevoflurane may increase the anticoagulant activities of Eptifibatide.Approved, Vet Approved
SRT501SRT501 may increase the anticoagulant activities of Eptifibatide.Investigational
StreptokinaseEptifibatide may increase the anticoagulant activities of Streptokinase.Approved, Investigational
SulodexideEptifibatide may increase the anticoagulant activities of Sulodexide.Approved, Investigational
TenecteplaseEptifibatide may increase the anticoagulant activities of Tenecteplase.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Eptifibatide.Investigational
TicagrelorEptifibatide may increase the anticoagulant activities of Ticagrelor.Approved
TiclopidineEptifibatide may increase the anticoagulant activities of Ticlopidine.Approved
TinzaparinEptifibatide may increase the anticoagulant activities of Tinzaparin.Approved
TioclomarolEptifibatide may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirTipranavir may increase the antiplatelet activities of Eptifibatide.Approved, Investigational
TirofibanEptifibatide may increase the anticoagulant activities of Tirofiban.Approved
TositumomabThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Tositumomab.Approved, Investigational
TranilastTranilast may increase the anticoagulant activities of Eptifibatide.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Eptifibatide.Approved
TreprostinilTreprostinil may increase the antiplatelet activities of Eptifibatide.Approved, Investigational
TriflusalEptifibatide may increase the anticoagulant activities of Triflusal.Approved, Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Trolamine salicylate.Approved
TroxerutinEptifibatide may increase the anticoagulant activities of Troxerutin.Investigational
UrokinaseEptifibatide may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
Vitamin EVitamin E may increase the antiplatelet activities of Eptifibatide.Approved, Nutraceutical, Vet Approved
VorapaxarEptifibatide may increase the anticoagulant activities of Vorapaxar.Approved
WarfarinEptifibatide may increase the anticoagulant activities of Warfarin.Approved
XimelagatranEptifibatide may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Guojie Ho, Antoinette Paone, Luciano Forni, Catherine De Tollenaere, Brice Bonnet, Christine Devijver, "Processes for preparing eptifibatide." U.S. Patent US20060036071, issued February 16, 2006.

US20060036071
General References
  1. Nguyen CM, Harrington RA: Glycoprotein IIb/IIIa receptor antagonists: a comparative review of their use in percutaneous coronary intervention. Am J Cardiovasc Drugs. 2003;3(6):423-36. [PubMed:14728062]
External Links
PubChem Substance
46505459
ChEMBL
CHEMBL1174
Therapeutic Targets Database
DAP000285
PharmGKB
PA449483
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Eptifibatide
ATC Codes
B01AC16 — Eptifibatide
AHFS Codes
  • 20:12.18 — Platelet Aggregation Inhibitors
FDA label
Download (87.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2CompletedTreatmentStrokes1
1, 2TerminatedTreatmentSickle Cell Disorders1
2CompletedTreatmentAcute Coronary Syndromes (ACS)1
2CompletedTreatmentBrain Infarction / Stroke, Ischemic / Strokes1
2CompletedTreatmentBrain Infarction / Strokes1
2CompletedTreatmentCoronary Heart Disease (CHD)1
2CompletedTreatmentStroke, Ischemic1
2RecruitingTreatmentAcute Coronary Syndromes (ACS) / Myocardial Infarction (MI) / Unstable Angina (UA)1
2RecruitingTreatmentStable Angina (SA) / Unstable Angina (UA)1
2TerminatedTreatmentPneumonia1
2TerminatedTreatmentST Elevation Myocardial Infarction (STEMI)1
2Unknown StatusTreatmentAcute Myocardial Infarction (AMI)1
2Unknown StatusTreatmentShock, Septic1
3CompletedSupportive CareCardiovascular Disease (CVD)1
3CompletedTreatmentAcute Coronary Syndromes (ACS)1
3CompletedTreatmentAcute Coronary Syndromes (ACS) / Myocardial Ischemia1
3CompletedTreatmentMyocardial Infarction (MI)1
3TerminatedTreatmentMyocardial Infarction (MI)1
4CompletedTreatmentCoronary Artery Disease / Myocardial Infarction (MI)1
4CompletedTreatmentNon ST Elevation Myocardial Infarction1
4TerminatedTreatmentAngioplasty1
4TerminatedTreatmentCoronary Artery Disease1
Not AvailableCompletedTreatmentStable Angina (SA)1

Pharmacoeconomics

Manufacturers
  • Schering corp
Packagers
Dosage forms
FormRouteStrength
InjectionIntravenous.75 mg/mL
InjectionIntravenous2 mg/mL
InjectionIntravenous20 mg/10mL
InjectionIntravenous200 mg/100mL
InjectionIntravenous75 mg/100mL
Injection, solutionIntravenous0.75 mg/ml
Injection, solutionIntravenous2 mg/ml
Injection, solutionIntravenous.75 mg/mL
SolutionIntravenous0.75 mg
SolutionIntravenous2 mg
Prices
Unit descriptionCostUnit
Integrilin 20 mg/10 ml vial12.41USD ml
Integrilin 200 mg/100 ml vial10.74USD ml
Integrilin 75 mg/100 ml vial3.88USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5686570No1994-11-112014-11-11Us
CA2133205No2007-04-172013-04-27Canada
US5807825No1995-09-152015-09-15Us

Properties

State
Liquid
Experimental Properties
PropertyValueSource
hydrophobicity-2.3Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
General Function
Virus receptor activity
Specific Function
Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Wil...
Gene Name
ITGB3
Uniprot ID
P05106
Uniprot Name
Integrin beta-3
Molecular Weight
87056.975 Da
References
  1. Amoroso G, van Boven AJ, van Veldhuisen DJ, Tio RA, Balje-Volkers CP, Petronio AS, van Oeveren W: Eptifibatide and abciximab exhibit equivalent antiplatelet efficacy in an experimental model of stenting in both healthy volunteers and patients with coronary artery disease. J Cardiovasc Pharmacol. 2001 Oct;38(4):633-41. [PubMed:11588534]
  2. Schror K, Weber AA: Comparative pharmacology of GP IIb/IIIa antagonists. J Thromb Thrombolysis. 2003 Apr;15(2):71-80. [PubMed:14618072]
  3. Fischer TH, Thatte HS, Nichols TC, Bender-Neal DE, Bellinger AD, Vournakis JN: Synergistic platelet integrin signaling and factor XII activation in poly-N-acetyl glucosamine fiber-mediated hemostasis. Biomaterials. 2005 Sep;26(27):5433-43. [PubMed:15860200]
  4. Weber AA, Jacobs C, Meila D, Weber S, Zotz RB, Scharf RE, Kelm M, Strauer BE, Schror K: No evidence for an influence of the human platelet antigen-1 polymorphism on the antiplatelet effects of glycoprotein IIb/IIIa inhibitors. Pharmacogenetics. 2002 Oct;12(7):581-3. [PubMed:12360110]
  5. Schwarz M, Katagiri Y, Kotani M, Bassler N, Loeffler C, Bode C, Peter K: Reversibility versus persistence of GPIIb/IIIa blocker-induced conformational change of GPIIb/IIIa (alphaIIbbeta3, CD41/CD61). J Pharmacol Exp Ther. 2004 Mar;308(3):1002-11. Epub 2003 Nov 14. [PubMed:14617694]
  6. Auer J, Berent R, Lassnig E, Weber T, Maurer E, Eber B: [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease]. Herz. 2003 Aug;28(5):393-403. [PubMed:12928738]
  7. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:33